Get started
Author

Peter Ian Joyce

Observed names: Peter I. Joyce, Peter Joyce
OpenAlex ID: A5032039751
Abstract 2065: A small molecule approach to drive novel neoantigen generation: First-in-class inhibitors of ERAP1 generate novel neoantigens driving anti-tumor effects
2022 · Andrew Leishman, Wayne Paes, et al. · Cancer Research · 3
553 First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition
2021 · Peter Joyce, Martin Quibell, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 3467: GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses
2023 · Andrew Leishman, Wayne Paes, et al. · Cancer Research · 1
1131 GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses
2022 · Peter Joyce, Andrew Leishman, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
446 Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition
2020 · Peter Joyce, Lesley Young, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
140 Development of first-in-class ERAP2 inhibitors to modulate the cancer immunopeptidome
2023 · Kristopher Clark, Sam Humphrey, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 4153: First-in-class inhibitors of ERAP1 alter the HLA-I-restricted cancer immunopeptidome leading to the generation of novel peptides presented for immune recognition
2022 · Wayne Paes, Andrew Leishman, et al. · Cancer Research
Abstract 1715: First in class inhibitors of ERAP1 have the potential to be a transformative immunotherapy in oncology
2021 · Andrew Leishman, Fergus Poynton, et al. · Cancer Research
Abstract 5551: Potent oral ERAP1 inhibitors modify the immunopeptidome in vivo and are novel immunotherapy agents
2020 · Jamie Ware, Patrick McIntyre, et al. · Cancer Research
Works count: 9
Citation count: 9
H-index: 2
I10-index:
Year
Topic
Type